| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S16763 R70393 |
Hernandez-Diaz, 2024 | Autism spectrum disorder (ASD) - At least two visits with codes for ASD - Median follow-up was 2 years | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 0.75 [0.37;1.52] | -/623 102/8,815 | - | 623 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17437 R73276 |
Madley-Dowd_SE (Topiramate) (Controls exposed to LTG), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Partial overlapping |
4.06 [1.68;9.78] C excluded (control group) |
6/71 53/2,383 | 59 | 71 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17438 R73271 |
Madley-Dowd_SE (Topiramate) (Controls unexposed, sick), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Partial overlapping | 2.79 [1.23;6.30] | 6/71 425/10,769 | 431 | 71 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17255 R72254 |
Madley-Dowd_UK (Topiramate) (Controls unexposed, sick) (Epilepsy), 2024 | Autism - ICD10 codes - Median follow up 5.41 (3.59-8.40) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 0.68 [0.08;5.36] | -/43 78/4,075 | - | 43 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15875 R65448 |
Dreier (Topiramate) (Epilepsy) (Controls exposed to LTG), 2023 | Autism spectrum disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
2.32 [1.10;4.88] C excluded (control group) |
8/290 64/5,288 | 72 | 290 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15876 R65457 |
Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 | Autism spectrum disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 1.93 [0.95;3.94] | 8/290 323/22,203 | 331 | 290 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9960 R48036 |
Bjørk (Topiramate) (Controls exposed to Lamotrigine, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
0.97 [0.10;9.00] C excluded (control group) |
1/6 13/76 | 14 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9955 R48037 |
Bjørk (Topiramate) (Controls unexposed, disease free), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, disease free excluded | Adjustment: No |
1.99 [0.23;17.00] C excluded (control group) |
1/6 6,907/75,497 | 6,908 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9957 R48038 |
Bjørk (Topiramate) (Controls unexposed, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: No | 1.81 [0.20;16.11] C | 1/6 27/272 | 28 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6183 R48028 |
Wood (Topiramate), 2015 | Score >30 (CARS) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 17.00 [0.13;2166.90] C | 0/1 0/9 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.54 [0.85;2.78] | 790 | 1,034 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Topiramate) (Controls unexposed, sick; 2: Topiramate) (Controls unexposed, sick) (Epilepsy; 3: Topiramate) (Epilepsy) (Controls unexposed, sick; 4: Topiramate) (Controls unexposed, sick; 5: Topiramate;
Asymetry test p-value = 0.7115 (by Egger's regression)
slope=0.2063 (0.5802); intercept=0.4500 (1.1331); t=0.3972; p=0.7115
excluded 9960, 9955, 15875, 17437